Growing Concerns Over Preventable Illnesses

A coalition of nearly twenty Dutch healthcare, patient advocacy, and senior citizen organizations has voiced strong concerns about the Netherlands’ adult vaccination rates compared to other European nations. The coalition, including prominent groups such as the KNMG Doctor Federation and the Professional Association for Nurses and Carers V&VN, argues that the slow adoption of proven vaccines leaves vulnerable populations at unneeded risk. Their campaign, titled Vooruit with vaccination, highlights the urgent need for improved access to essential preventative care.

Specific Vaccines Spark Debate

The core of the issue lies in the limited availability of vaccines recommended by the Health Council, particularly those targeting shingles (herpes zoster) and newer, more effective influenza strains. while these vaccines have demonstrated important benefits, they are not yet widely accessible or free for eligible adults.

The Shingles Vaccine Dilemma

Demand for the recombinant zoster vaccine (RZV) has surged, overwhelming general practitioners and public health services (GGDs). Shingles, a painful condition caused by the reactivation of the varicella-zoster virus (the same virus that causes chickenpox), can lead to debilitating nerve pain lasting for years after the initial outbreak. The infection manifests as itchy, painful blisters, often appearing in a belt-like pattern around the torso, accompanied by fever.

While the RZV vaccine boasts a 90% effectiveness rate in preventing shingles infections, it is currently only reimbursed for specific high-risk groups. Healthy individuals over 50 face a significant out-of-pocket cost of approximately €500 for the required two-dose course. This is despite the Health Council’s 2019 proposal to include all individuals over 60 in the reimbursement program.

enhanced Flu Vaccines: A Missed Prospect?

Recent advancements in influenza vaccine technology have yielded new formulations that offer superior protection compared to the standard annual flu shot. these newer vaccines have demonstrated a 10-30% betterment in preventing hospital admissions, particularly among the elderly. In 2024, the Health Council advised integrating one of these advanced vaccines into the National Influenza Prevention Program.

Cost-Effectiveness Concerns Stall Progress

The widespread distribution of both the shingles and enhanced flu vaccines is hindered by cost considerations. the price of the shingles vaccine currently exceeds the Dutch government’s threshold for cost-effectiveness,which is based on the Quality-Adjusted Life Year (QALY) metric,capped at €20,000. While the Health Council’s latest report lacked clarity on the pricing of the updated flu vaccine,the shingles vaccine is already available to older adults in countries like Germany,greece,and Luxembourg.

A Health Economist’s Viewpoint

Health economist Matthijs Versteegh cautions against simplistic comparisons of vaccine availability across different European countries. The fact that other countries offer a drug faster or earlier does not mean that it is a better decision. It is indeed very easy to point out what is available in other countries, but it is frequently enough left out what is not there. Free does not exist.

Versteegh emphasizes the importance of the Dutch government’s careful evaluation process, arguing that seemingly financial decisions have significant health implications.Money that you spend on these vaccines do not have left for other social spending that perhaps produce more health gains for the same euro.

The Financial Implications of worldwide Vaccination

Estimates suggest that vaccinating all 60-year-olds against shingles would encompass approximately 250,000 adults annually, with a one-time catch-up campaign targeting around five million individuals over 60. The projected cost for the initial five years is €185 million, followed by €32 million in subsequent years. potential healthcare cost savings are estimated at a maximum of €11 million per year.

The Netherlands’ Cautious Approach to Vaccine Implementation

The Netherlands is facing scrutiny over its approach to implementing new vaccination programs.While some experts defend the nation’s thorough evaluation process as prudent, others argue that it’s a case of short-sighted cost-saving measures that ultimately harm public health. This debate centers on whether the country’s rigorous cost-effectiveness analyses are delaying access to crucial preventive care.

Economic Considerations vs. Public Health Imperatives

Matthijs Versteegh, a health expert, highlights the inherent challenge of preventive interventions: a large number of healthy individuals must be vaccinated to prevent a relatively small number of illnesses. This necessitates careful consideration of whether the overall disease burden justifies the expenditure. Ultimately, it is a distribution issue that the government should think about, Versteegh states, emphasizing the need for a balanced approach.

Delays in National Vaccination Programs: A Case Study

Though,Versteegh also criticizes the slow decision-making processes within the national vaccination program. He points to the rotavirus vaccine,recommended for children under six by the Health Council in 2017 due to its cost-effectiveness,yet only implemented in 2024. I can’t imagine that all those years have been negotiated over the price. If processes can be faster without compromising on care, then that has to be done. This seven-year delay raises questions about the efficiency of the Dutch system.

A Critical Perspective on Dutch Policy

Maarten Postma, a health economist at the University of Groningen, offers a more critical assessment of Dutch policy. Drawing on his experience advising the British government on vaccine implementation, Postma observes a stark contrast in approaches. Our government seems to use the argument of cost-effectiveness, or the lack of clarity about it, mainly to keep the resources the vaccination program.

Comparing the Netherlands to the United Kingdom

Postma notes that the United Kingdom has already widely distributed several vaccines not yet reimbursed in the Netherlands, despite placing even greater emphasis on cost-effectiveness. He cites the RSV vaccine, which protects both infants and the elderly from respiratory syncytial virus, as a prime example.If they have been able to negotiate a reasonable price for the vaccine, there is no reason to think that we could not do that. This comparison suggests that the Netherlands may be missing opportunities to protect its population.

Prevention: An Investment in the Future

While Versteegh advocates for careful consideration of costs, Postma views the Dutch approach as short-sighted. Certainly prevention does not have the tide, because then you will invest now, while the benefits come later. I think the Netherlands is too economical in that. He argues that the Netherlands, as a wealthy nation, should prioritize preventive healthcare, even if the benefits are not promptly apparent. This perspective aligns with the growing recognition of the long-term economic and social benefits of preventative medicine, as highlighted in a 2023 World Health Organization report on investing in prevention.